Home › Merck Announces Presentation of New Findings for ZEPATIER (Elbasvir and Grazoprevir) in Patients with Chronic Hepatitis C at The Liver Meeting
 

Keywords :   


Merck Announces Presentation of New Findings for ZEPATIER (Elbasvir and Grazoprevir) in Patients with Chronic Hepatitis C at The Liver Meeting

2016-11-12 14:00:00| Merck.com - Corporate News

Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced results from multiple analyses at The Liver Meeting 2016, which provide additional evidence supporting the use of ZEPATIER (elbasvir and grazoprevir) 50mg/100mg tablets in chronic hepatitis C virus (HCV) genotype (GT) 1- or GT4-infected patient populations, including those who receive opioid agonist therapy (OAT), are infected with chronic HCV GT1b, use proton pump inhibitors (PPIs) or have moderate kidney disease.

Tags: the meeting presentation patients

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
29.04Sherwin-Williams Reports 1Q 2024 Financial Results
29.04Power cut causes disruption at major airport
29.04New law aims to protect devices from hackers
28.04National Coalition to End Period Poverty Launched
28.04PZ Cussons To Sell St. Tropez & Aveda Launches Curl Care Line
28.04Beauty Enthusiasts Eye Burgundy Mascara
28.04Distinctive Assets Distributes Mother\'s Day in Hollywood Celebrity Gift Boxes
28.04Musk in China to discuss full self driving - reports
More »